Cancer Letters Submission Guide

Source: Clarivate JCR 2024, Elsevier editorial disclosures (accessed April 2026).

Source: Cancer Letters author guidelines.

Use this page when deciding:

• whether the cancer-biology contribution is mechanistic

• whether functional validation is rigorous

• whether translational relevance is direct

• a clear cancer-biology mechanism contribution

• rigorous functional validation

• in-vivo or clinical validation

• translational relevance

• a cover letter establishing the cancer-biology contribution

• Descriptive observations without mechanism.

• Weak functional validation.

• Missing in-vivo or clinical validation.

• Drug discovery without cancer-biology focus.

Cancer Letters is a flagship cancer-research journal.

Mechanism + translational standard: the journal differentiates from Cancer Research (broader) and specialty cancer journals by demanding cancer-biology mechanism with translational relevance.

Functional-validation expectation: editors expect mutants, knockouts, or comparable functional evidence.

The 40-50% desk rejection rate: decisive editorial screen.

The strongest Cancer Letters editor-facing notes establish:

• the cancer-biology mechanism contribution

• the functional validation

• the in-vivo or clinical evidence

• the translational relevance

Cancer Letters requires these at first submission:

• Cover letter explicitly establishing the mechanistic or translational cancer-biology contribution (the journal rejects purely descriptive observations)

• Declaration of competing interests for all authors

• Ethics approval statement for human-subject or animal work (IRB/IACUC numbers required)

• Informed consent statement for clinical samples

• Data availability statement with repository links for sequencing, transcriptomic, or proteomic data

• CRediT author contributions statement

• Four or more suggested reviewers with no recent collaboration history

For Cancer Letters submissions, the most common artifact-related desk-reject is missing or generic ethics statements. Elsevier intake reviewers flag specific IRB and IACUC numbers; vague "approval was obtained" language commonly triggers a return for revision before scope screen.

For Cancer Letters submissions, the editorial timeline runs through four phases. The journal weights functional cancer-biology mechanism heavily; published data indicates roughly 40-50% of submissions are desk-rejected at the editorial screen and overall acceptance runs 20-25%.

Day 0 to 5: Editorial Manager intake and editor assignment

Elsevier intake handles format compliance plus the ethics-statement check. The handling Editor assignment lands within 5 days; oncology papers route to subject editors matching the cancer subfield (molecular oncology, immuno-oncology, translational, radiation biology). The most common Day 0-5 hold-up: cover letters that frame the contribution as descriptive rather than mechanistic.

Day 5 to 21: Editor scope and mechanism screen

Cancer Letters' editor filter prioritizes functional cancer-biology mechanism contributions or translational evidence. The most common Day 5-21 desk reject in our review work: descriptive transcriptomic or proteomic surveys without functional perturbation experiments. Roughly 40-50% of submissions reach this stage and exit via desk rejection rather than peer review.

Week 3 to 10: Peer review

Standard 2-3 reviewers, 4-8 week first decision target. Reviewer mix typically includes one mechanistic-cancer-biology expert plus one application-domain specialist (clinical, translational, or methodology). Submissions missing functional validation or in vivo confirmation extend reviewer dialogue by 3-5 weeks.

Week 10 to 24: Decision, revision, and APC

Major revision is the standard first decision at Cancer Letters; rejections at peer review usually cite missing mechanistic depth rather than execution. Revision rounds typically settle at 2 (rarely 3 for accepted papers). Total submission-to-acceptance: 5-8 months for accepted papers. Hybrid open-access option available with APC at acceptance.

• Is Cancer Letters a good journal?

Before upload, run your manuscript through a Cancer Letters mechanism readiness check.

Use the guide for portal, routing, and policy details; use the manuscript check for the editor-facing fit call. The review tells you whether your paper clears the Cancer Letters fit check before upload, especially around descriptive observations without functional cancer-biology studies, weak functional validation, and missing in-vivo or clinical validation. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Source limitations: official Cancer Letters journal and publisher pages define scope, article types, and submission mechanics, but they do not publish manuscript-level desk decisions for Cancer Letters; the patterns below combine public guidance, recent issue review, and anonymized Manusights pre-submission review work for this journal family.

Across cancer manuscripts targeting Cancer Letters, three patterns appear most often in desk-rejected submissions.

Manusights pre-submission pattern analysis shows many Cancer Letters desk rejections trace to descriptive observations without mechanism. The same pattern analysis often finds these cases involve weak functional validation. A related pattern is that these cases often arise from missing in-vivo or clinical validation.

Descriptive observations without functional cancer-biology studies

Cancer Letters editors look for mechanism, not just observations. We observe submissions reporting expression patterns or correlations without functional validation routinely desk-rejected.

For Cancer Letters specifically, this is visible in the abstract, central figure, methods section, and cover letter. The abstract reports that marker X is upregulated in cancer Y, but the manuscript never tests whether X drives proliferation, invasion, immune escape, treatment resistance, metastasis, or another cancer-relevant phenotype. The figure set shows correlation plots and survival curves but no perturbation experiment. The cover letter calls the finding translational even though the paper has not connected the observation to a cancer mechanism or therapeutic decision.

Check descriptive observations without functional cancer biology studies before submitting to Cancer Letters →

Weak functional validation

Editors expect mutants, knockouts, knockdowns, or comparable functional evidence. We see manuscripts with thin functional experiments routinely returned.

The component-level signal is the functional validation package: knockdown or knockout design, rescue experiment, controls, sample-size logic, replicate structure, statistical analysis, and figure captions. Cancer Letters manuscripts are weaker when the key functional claim rests on one cell line, one assay, or a supplementary-only control. They are stronger when main figures include perturbation, rescue, dose or time response, and mechanistic readout tied to the cancer biology question.

Check weak functional validation before submitting to Cancer Letters →

Missing in-vivo or clinical validation

Cancer Letters specifically expects animal models or patient samples. We find papers reporting only cell-culture data without in-vivo or clinical evidence routinely declined. A Cancer Letters mechanism readiness check can identify whether the package supports a submission.

The affected components are the main figures, supplementary evidence, ethics statement, patient-sample description, animal-model methods, data availability statement, and translational paragraph in the discussion. If patient material, animal evidence, organoid data, or clinically anchored validation exists only as a brief supplement, the paper can look less mature than it is. If no in-vivo or clinical validation exists, the submission may still be scientifically useful, but Cancer Letters may not be the best target yet.

Clarivate JCR 2024 bibliometric data places Cancer Letters among top cancer-research journals.

Check missing in vivo or clinical validation before submitting to Cancer Letters →

Before the reviewer-invitation stage, read the Cancer Letters package against the same risks this guide flags in the Manusights section. The practical question is whether the abstract, cover letter, figures or tables, methods, reporting statements, supplementary files, and references all make the journal choice obvious.

• If the abstract still points toward descriptive observations without functional cancer-biology studies, revise the central claim before upload.

• If the evidence package leaves weak functional validation, strengthen the methods, controls, figures, or supplementary material rather than expecting reviewers to infer it.

• If the cover letter cannot resolve missing in-vivo or clinical validation, compare the target journal against the adjacent venues named above before submitting.

Use these nearby guides when the target journal is still uncertain:

• Cancer Letters submission guide

• Cellular and Molecular Life Sciences Submission Guide

• Nature Biotechnology Submission Guide

• JCI Insight Submission Guide

• Molecular Psychiatry Submission Guide

• Molecular Systems Biology Submission Guide

• Journal of Clinical Oncology Submission Guide

• Annals of Oncology Submission Guide

• Nature Nanotechnology Submission Guide

• Psychological Review Submission Guide

• Nature Reviews Neuroscience Submission Guide

In pre-submission diagnostic work for top cancer-research journals, we consistently see four signals that distinguish strong submissions from weak ones. First, the contribution must be mechanistic, not descriptive. Second, functional validation should include mutants, knockouts, or comparable experiments. Third, in-vivo or clinical validation should be included. Fourth, translational relevance should be direct.

For Cancer Letters-targeted manuscripts, the single most consistent feedback class we deliver in pre-submission diagnostics for Cancer Letters is the descriptive-versus-mechanistic distinction. Cancer Letters editors expect mechanism, not just expression or correlation observations. Submissions framed as "we observed expression of X in cancer Y" routinely receive "where is the mechanism?" feedback during desk screening. We coach authors to lead with the mechanism question and frame the observation in service of that question.

Papers framed as "we tested whether X drives cancer phenotype Y by combining functional, in-vivo, and patient-sample analysis" receive better editorial traction. The same logic applies across mechanism-focused cancer journals: editors are operating with limited slot inventory, and the submissions that get traction lead with the mechanism question.

For Cancer Letters-targeted manuscripts, beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for Cancer Letters. First, manuscripts where the abstract reports observations without articulating the cancer-biology mechanism are flagged at desk for descriptive framing. We recommend the abstract's central sentences state the mechanism question, the experimental approach, and the mechanistic finding.

Second, manuscripts where in-vivo data is reported only in supplementary materials are flagged for translational framing gaps. We recommend integrating in-vivo data into main figures. Third, manuscripts that lack engagement with Cancer Letters' recent issues are at risk of being told the contribution doesn't fit the publication conversation.

For Cancer Letters-targeted manuscripts, the strongest manuscripts we coach distinguish themselves on three operational behaviors. First, they confine the cover letter to one page and use it to make the case for fit, contribution, and significance, not to summarize the abstract. Second, they include a one-sentence elevator pitch in the cover letter's opening that the editor can use when discussing the manuscript internally.

Third, they identify the specific recent papers in the journal that this manuscript builds on and the specific competing or contradicting work; this signals the authors are operating inside the publication conversation rather than outside it.

Source limitations: This Cancer Letters Submission Guide page combines official guidance where available, public publisher or product materials, and Manusights editorial analysis for Cancer Letters; it is an independent readiness screen, not official guidance from the journal, publisher, or service. In our work, we observe that editors specifically screen Cancer Letters submissions for fit, evidence completeness, and reviewer-risk signals before the manuscript can benefit from strong prose.

For the related journal overview, see Cancer Letters submission guide. In our work on Cancer Letters submissions, we observe that editors specifically screen the abstract, first figures, cover letter, and evidence package for whether the manuscript answers the journal's stated fit test; our analysis of Cancer Letters pages treats those checks as submission-risk signals, not as official guidance.